tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARQT Stock Latest News

Buy Rating on Arcutis Biotherapeutics Driven by Zoryve Commercial Momentum, Pipeline Upside, and Favorable Risk‑Reward Valuation
RatingsBuy Rating on Arcutis Biotherapeutics Driven by Zoryve Commercial Momentum, Pipeline Upside, and Favorable Risk‑Reward Valuation
5d ago
ARQT
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating
PremiumRatings
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating
5d ago
ARQT
Arcutis Biotherapeutics sees FY26 ZORYVE revenue $455M-$470M
PremiumThe Fly
Arcutis Biotherapeutics sees FY26 ZORYVE revenue $455M-$470M
6d ago
ARQT
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
PremiumRatings
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target on Arcutis Biotherapeutics
23d ago
ARQT
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
PremiumCompany Announcements
Arcutis Biotherapeutics Appoints Amit Munshi as New Director
1M ago
8K
ARQT
Netflix target cut, Five Below target raised: Wall Street’s top analyst calls
PremiumThe FlyNetflix target cut, Five Below target raised: Wall Street’s top analyst calls
2M ago
DE
ANF
Arcutis Biotherapeutics price target raised to $37 from $32 at Mizuho
Premium
The Fly
Arcutis Biotherapeutics price target raised to $37 from $32 at Mizuho
2M ago
ARQT
Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE
Premium
The Fly
Arcutis Biotherapeutics announces FDA acceptance of sNDA for ZORYVE
2M ago
ARQT
Arcutis Biotherapeutics completes enrollment in INTEGUMENT-INFANT Phase 2 study
PremiumThe Fly
Arcutis Biotherapeutics completes enrollment in INTEGUMENT-INFANT Phase 2 study
2M ago
ARQT
Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published
PremiumThe Fly
Arcutis Biotherapeutics announces data from Phase 2 study of ZORYVE published
2M ago
ARQT
Arcutis partners with Tori Spelling, Stella McDermott for campaign
PremiumThe Fly
Arcutis partners with Tori Spelling, Stella McDermott for campaign
3M ago
ARQT
Arcutis Biotherapeutics announces commercial launch of ZORYVE cream
PremiumThe Fly
Arcutis Biotherapeutics announces commercial launch of ZORYVE cream
3M ago
ARQT
Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs
PremiumThe FlyArcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs
3M ago
ARQT
Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho
Premium
The Fly
Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho
3M ago
ARQT
Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
Premium
The Fly
Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
3M ago
ARQT
Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
PremiumCompany Announcements
Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
3M ago
ARQT
Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
PremiumRatings
Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
3M ago
ARQT
Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
PremiumThe Fly
Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
3M ago
W
ARE
Arcutis Biotherapeutics rises 26.5%
PremiumThe Fly
Arcutis Biotherapeutics rises 26.5%
3M ago
ARQT
Arcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy Rating
PremiumRatingsArcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy Rating
3M ago
ARQT
Arcutis Biotherapeutics rises 24.7%
Premium
The Fly
Arcutis Biotherapeutics rises 24.7%
3M ago
ARQT
Arcutis Biotherapeutics reports Q3 EPS 6c, consensus (10c)
Premium
The Fly
Arcutis Biotherapeutics reports Q3 EPS 6c, consensus (10c)
3M ago
ARQT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >